Text/HTML

We will be performing maintenance on this site on March 24, 2024 starting at 6:00 am until 8:00 am.  We apologize for the inconvenience.  


Mobile App

Google Play Apple Store

EasyDNNNews

Looking to the Future: A New Era of PAH Therapy
AMA/ANCC/ACPE Activity
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Over the past two decades, research has vastly improved the understanding of the pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension (PAH). While no therapies have been approved to target new mechanisms of action in more than 15 years, multiple phase 2 and phase 3 clinical trials of novel therapies are underway. Further, management decisions regarding practical issues must also be addressed. Emerging research in accurate phenotyping of PH may also improve customization of therapies and prognostication as well as to increase the homogeneity of study cohorts in clinical trials. Improvements in the care of PAH patients depends on improving clinician awareness of the latest research into new diagnostic techniques, medications, and monitoring. This on-demand presentation is designed for the multi-disciplinary medical team and addresses the practical challenges of managing patients in the new era of PAH therapy.

Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.





Ronald Oudiz, MD, FACP, FACC, FCCP Ronald Oudiz, MD, FACP, FACC, FCCP
Professor of Medicine
The David Geffen School of Medicine at UCLA
Chief, Division of Cardiology
Director, Pulmonary Hypertension Clinic
Harbor-UCLA Medical Center  
Robert Schilz, DO, PhD Robert Schilz, DO, PhD
Director, Pulmonary Vascular Disease and Lung Transplantation
University Hospitals of Cleveland
Associate Professor of Medicine
Case School of Medicine

20

Supported by independent educational grants from United Therapeutics, a public benefit company; Bayer U.S.; and Actelion Pharmaceuticals U.S., Inc.,

A Janssen Pharmaceutical Company of Johnson & Johnson


Launch Date: June 29, 2023

Release Date: June 14, 2023

Expiration Date: May 31, 2024

May 31, 2024
Mini Module
7581
TalkingPAH2022_WebBanner(1150px).gif
Pulmonology